DrugPatentWatch Database Preview
Horizon Pharma Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for HORIZON PHARMA, and when can generic versions of HORIZON PHARMA drugs launch?
HORIZON PHARMA has three approved drugs.
There are twenty-four US patents protecting HORIZON PHARMA drugs.
There are one hundred and one patent family members on HORIZON PHARMA drugs in thirty-nine countries and nine supplementary protection certificates in eight countries.
Summary for Horizon Pharma
| International Patents: | 101 |
| US Patents: | 24 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 3 |
| Patent Litigation for Horizon Pharma: | See patent lawsuits for Horizon Pharma |
Drugs and US Patents for Horizon Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-001 | Apr 30, 2013 | RX | Yes | No | Start Trial | Start Trial | |||||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-001 | Apr 30, 2013 | RX | Yes | No | Start Trial | Start Trial | |||||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | 9,925,158 | Start Trial | Y | Y | Start Trial | ||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | GRANULE;ORAL | 213491-002 | Feb 14, 2020 | RX | Yes | Yes | 10,143,665 | Start Trial | Start Trial | ||||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | 9,198,882*PED | Start Trial | Y | Start Trial | |||
| Horizon Pharma Usa | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | RX | Yes | No | 9,040,085 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Horizon Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Horizon Pharma Usa | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-001 | Jul 26, 2012 | 6,488,960 | Start Trial |
| Horizon Pharma Usa | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | 6,677,326 | Start Trial |
| Horizon Pharma Usa | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-001 | Jul 26, 2012 | 6,677,326 | Start Trial |
| Horizon Pharma Usa | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | 6,488,960 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HORIZON PHARMA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 1 mg, 2 mg, and 5 mg | ➤ Subscribe | 2012-11-26 |
International Patents for Horizon Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2049123 | Start Trial |
| World Intellectual Property Organization (WIPO) | 0224206 | Start Trial |
| Morocco | 30665 | Start Trial |
| Eurasian Patent Organization | 200900259 | Start Trial |
| Lithuania | 2535044 | Start Trial |
| Croatia | P20130148 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Horizon Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1919458 | 194 50001-2014 | Slovakia | Start Trial | PRODUCT NAME: MERKAPTAMIN; FIRST REGISTRATION: EU/1/13/861, 20130906 |
| 1919458 | SPC/GB14/019 | United Kingdom | Start Trial | PRODUCT NAME: CYSTEAMINE; REGISTERED: UK EU/1/13/861 20130910 |
| 1919458 | C300649 | Netherlands | Start Trial | PRODUCT NAME: CYSTEAMINE; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130906 |
| 1919458 | 122014000023 | Germany | Start Trial | PRODUCT NAME: CYSTEAMIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/861 20130906 |
| 1919458 | 2014C/018 | Belgium | Start Trial | PRODUCT NAME: CYSTEAMINE; AUTHORISATION NUMBER AND DATE: EU/1/13/861 20130910 |
| 1919458 | 19/2014 | Austria | Start Trial | PRODUCT NAME: CYSTEAMIN; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130910 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
